| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 32 | 2024 | 1189 | 2.600 |
Why?
|
| Graft vs Host Disease | 15 | 2024 | 622 | 1.310 |
Why?
|
| Hodgkin Disease | 8 | 2022 | 298 | 1.170 |
Why?
|
| T-Lymphocytes | 16 | 2024 | 1814 | 1.100 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2016 | 178 | 0.880 |
Why?
|
| Salvage Therapy | 3 | 2021 | 202 | 0.850 |
Why?
|
| Lymphoma | 4 | 2021 | 335 | 0.760 |
Why?
|
| Antigens, Neoplasm | 5 | 2021 | 407 | 0.720 |
Why?
|
| Transplantation, Autologous | 13 | 2022 | 285 | 0.680 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2021 | 170 | 0.670 |
Why?
|
| Transplantation, Homologous | 20 | 2024 | 691 | 0.620 |
Why?
|
| Herpesvirus 4, Human | 11 | 2018 | 674 | 0.560 |
Why?
|
| Immunosuppressive Agents | 4 | 2014 | 695 | 0.530 |
Why?
|
| Bone Marrow Transplantation | 5 | 2014 | 620 | 0.530 |
Why?
|
| Transplantation Conditioning | 9 | 2022 | 300 | 0.530 |
Why?
|
| T-Lymphocytes, Cytotoxic | 8 | 2013 | 522 | 0.510 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2018 | 888 | 0.440 |
Why?
|
| Alemtuzumab | 7 | 2024 | 88 | 0.440 |
Why?
|
| Skin Ulcer | 1 | 2014 | 33 | 0.440 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2013 | 809 | 0.440 |
Why?
|
| Thalidomide | 1 | 2014 | 41 | 0.440 |
Why?
|
| Lymphoma, T-Cell | 2 | 2018 | 65 | 0.400 |
Why?
|
| Middle Aged | 42 | 2024 | 29264 | 0.390 |
Why?
|
| Multiple Myeloma | 3 | 2021 | 201 | 0.380 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2013 | 93 | 0.380 |
Why?
|
| Herpesvirus 6, Human | 3 | 2017 | 55 | 0.370 |
Why?
|
| Antibodies, Monoclonal | 6 | 2008 | 1068 | 0.350 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2016 | 150 | 0.340 |
Why?
|
| Adult | 40 | 2024 | 31842 | 0.340 |
Why?
|
| Roseolovirus Infections | 2 | 2007 | 30 | 0.340 |
Why?
|
| Stem Cell Transplantation | 4 | 2006 | 250 | 0.330 |
Why?
|
| Antigens, CD19 | 6 | 2018 | 181 | 0.320 |
Why?
|
| Antilymphocyte Serum | 3 | 2006 | 57 | 0.310 |
Why?
|
| Interleukin-2 | 4 | 2014 | 250 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 1314 | 0.300 |
Why?
|
| Burkitt Lymphoma | 2 | 2006 | 141 | 0.290 |
Why?
|
| Gout | 1 | 2011 | 167 | 0.290 |
Why?
|
| CD40 Ligand | 4 | 2011 | 65 | 0.290 |
Why?
|
| Aged | 25 | 2024 | 21641 | 0.290 |
Why?
|
| Leukemia | 3 | 2022 | 380 | 0.290 |
Why?
|
| Male | 51 | 2024 | 65798 | 0.280 |
Why?
|
| Lymphoma, Follicular | 1 | 2007 | 30 | 0.270 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2013 | 26 | 0.270 |
Why?
|
| Paramyxoviridae Infections | 1 | 2007 | 49 | 0.270 |
Why?
|
| Metapneumovirus | 1 | 2007 | 52 | 0.270 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2018 | 169 | 0.270 |
Why?
|
| Paresis | 1 | 2006 | 33 | 0.260 |
Why?
|
| Cancer Vaccines | 4 | 2011 | 190 | 0.260 |
Why?
|
| Rituximab | 3 | 2022 | 164 | 0.260 |
Why?
|
| Hemoglobin SC Disease | 1 | 2006 | 11 | 0.260 |
Why?
|
| Humans | 68 | 2024 | 133564 | 0.260 |
Why?
|
| Viral Matrix Proteins | 5 | 2018 | 110 | 0.260 |
Why?
|
| Leukemia, Myeloid | 1 | 2006 | 82 | 0.250 |
Why?
|
| Cytomegalovirus Infections | 2 | 2024 | 229 | 0.240 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2020 | 502 | 0.240 |
Why?
|
| Cytokines | 1 | 2011 | 1396 | 0.240 |
Why?
|
| Antibodies, Neoplasm | 5 | 2008 | 60 | 0.240 |
Why?
|
| Hematologic Neoplasms | 5 | 2021 | 294 | 0.230 |
Why?
|
| Female | 46 | 2024 | 71548 | 0.230 |
Why?
|
| Young Adult | 11 | 2022 | 9875 | 0.230 |
Why?
|
| Antiviral Agents | 2 | 2024 | 824 | 0.220 |
Why?
|
| Lymphoma, B-Cell | 3 | 2018 | 149 | 0.220 |
Why?
|
| Quinazolines | 1 | 2024 | 184 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 1350 | 0.210 |
Why?
|
| Genetic Therapy | 3 | 2018 | 733 | 0.210 |
Why?
|
| Tissue Donors | 6 | 2021 | 523 | 0.200 |
Why?
|
| Recurrence | 10 | 2022 | 1468 | 0.200 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 276 | 0.200 |
Why?
|
| Adolescent | 17 | 2022 | 20522 | 0.200 |
Why?
|
| Lymphocyte Transfusion | 2 | 2021 | 58 | 0.190 |
Why?
|
| Treatment Outcome | 19 | 2018 | 12988 | 0.190 |
Why?
|
| Carmustine | 1 | 2022 | 25 | 0.190 |
Why?
|
| Neomycin | 2 | 2000 | 37 | 0.190 |
Why?
|
| Melphalan | 1 | 2022 | 45 | 0.190 |
Why?
|
| Graft vs Leukemia Effect | 2 | 2021 | 36 | 0.190 |
Why?
|
| Bone Marrow | 2 | 2021 | 335 | 0.190 |
Why?
|
| Cytarabine | 1 | 2022 | 100 | 0.190 |
Why?
|
| Seizures | 1 | 2006 | 889 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2021 | 568 | 0.170 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 129 | 0.160 |
Why?
|
| Bone Marrow Cells | 1 | 2021 | 273 | 0.160 |
Why?
|
| Tumor Escape | 2 | 2018 | 65 | 0.150 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 11 | 0.150 |
Why?
|
| Lymphocyte Depletion | 3 | 2024 | 125 | 0.150 |
Why?
|
| Voriconazole | 1 | 2018 | 34 | 0.150 |
Why?
|
| Antigens, CD | 4 | 2011 | 452 | 0.140 |
Why?
|
| Acute Disease | 4 | 2011 | 1190 | 0.140 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2018 | 70 | 0.140 |
Why?
|
| Antipyrine | 2 | 1988 | 4 | 0.140 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 22 | 0.140 |
Why?
|
| Diltiazem | 2 | 1988 | 14 | 0.140 |
Why?
|
| DNA Viruses | 1 | 2017 | 34 | 0.140 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2018 | 294 | 0.140 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2006 | 34 | 0.130 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2016 | 29 | 0.130 |
Why?
|
| Genetic Markers | 1 | 1998 | 631 | 0.130 |
Why?
|
| Child | 16 | 2022 | 25762 | 0.130 |
Why?
|
| Retrospective Studies | 10 | 2024 | 17402 | 0.120 |
Why?
|
| Prognosis | 4 | 2021 | 5076 | 0.120 |
Why?
|
| Vidarabine | 3 | 2010 | 78 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 317 | 0.110 |
Why?
|
| Leukapheresis | 1 | 2013 | 14 | 0.100 |
Why?
|
| Blood Donors | 1 | 2013 | 61 | 0.100 |
Why?
|
| Viruses | 1 | 2014 | 125 | 0.100 |
Why?
|
| Lung Diseases | 2 | 2009 | 403 | 0.100 |
Why?
|
| Remission Induction | 5 | 2016 | 307 | 0.100 |
Why?
|
| Time Factors | 7 | 2018 | 6577 | 0.100 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 1307 | 0.100 |
Why?
|
| Azoles | 1 | 2012 | 8 | 0.100 |
Why?
|
| Cushing Syndrome | 1 | 2012 | 21 | 0.100 |
Why?
|
| Budesonide | 1 | 2012 | 21 | 0.090 |
Why?
|
| Gene Transfer Techniques | 2 | 2011 | 365 | 0.090 |
Why?
|
| Colchicine | 1 | 2011 | 39 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 247 | 0.090 |
Why?
|
| Immunophenotyping | 4 | 2016 | 342 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 63 | 0.090 |
Why?
|
| Virus Diseases | 1 | 2014 | 289 | 0.090 |
Why?
|
| Quality of Life | 1 | 2021 | 2147 | 0.090 |
Why?
|
| Cytomegalovirus | 3 | 2024 | 270 | 0.090 |
Why?
|
| CD28 Antigens | 1 | 2011 | 81 | 0.090 |
Why?
|
| Retroviridae | 3 | 2016 | 198 | 0.090 |
Why?
|
| Allopurinol | 1 | 2011 | 76 | 0.090 |
Why?
|
| Primary Myelofibrosis | 1 | 2011 | 50 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2013 | 563 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 550 | 0.080 |
Why?
|
| Steroids | 1 | 2011 | 213 | 0.080 |
Why?
|
| Transplantation Chimera | 2 | 2008 | 44 | 0.080 |
Why?
|
| Lymphocyte Subsets | 1 | 2009 | 41 | 0.080 |
Why?
|
| Follow-Up Studies | 5 | 2018 | 5461 | 0.080 |
Why?
|
| Cell Proliferation | 5 | 2018 | 2553 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 315 | 0.080 |
Why?
|
| Histocompatibility | 2 | 2006 | 50 | 0.080 |
Why?
|
| DNA, Viral | 2 | 2007 | 501 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 1386 | 0.080 |
Why?
|
| Adenoviridae | 4 | 2013 | 610 | 0.080 |
Why?
|
| Theophylline | 1 | 1988 | 30 | 0.070 |
Why?
|
| Verapamil | 1 | 1988 | 58 | 0.070 |
Why?
|
| Virus Integration | 1 | 2007 | 40 | 0.070 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 111 | 0.070 |
Why?
|
| Lymphocyte Activation | 3 | 2018 | 724 | 0.070 |
Why?
|
| Encephalitis, Viral | 1 | 2007 | 21 | 0.070 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2018 | 79 | 0.070 |
Why?
|
| Minoxidil | 1 | 1986 | 4 | 0.070 |
Why?
|
| Antigen-Presenting Cells | 1 | 2007 | 133 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 1712 | 0.070 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2006 | 13 | 0.060 |
Why?
|
| Filgrastim | 1 | 2006 | 13 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2016 | 1596 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2510 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2006 | 506 | 0.060 |
Why?
|
| Anemia, Aplastic | 1 | 2006 | 62 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2016 | 815 | 0.060 |
Why?
|
| Benzazepines | 1 | 1986 | 61 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2008 | 191 | 0.060 |
Why?
|
| Immune System Diseases | 1 | 2006 | 50 | 0.060 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 57 | 0.060 |
Why?
|
| Leukemia, B-Cell | 1 | 2005 | 26 | 0.060 |
Why?
|
| Lymphocyte Count | 3 | 2014 | 125 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2008 | 553 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 292 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2013 | 971 | 0.060 |
Why?
|
| Leukocyte Common Antigens | 1 | 2005 | 93 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 1850 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2008 | 629 | 0.060 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2004 | 15 | 0.060 |
Why?
|
| Acetates | 1 | 2024 | 80 | 0.060 |
Why?
|
| Myelin Basic Protein | 1 | 2004 | 69 | 0.050 |
Why?
|
| Drug Interactions | 3 | 2012 | 261 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 445 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2010 | 820 | 0.050 |
Why?
|
| Herpesviridae Infections | 1 | 2004 | 147 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 118 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2006 | 456 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2005 | 468 | 0.050 |
Why?
|
| Cell Line | 3 | 2013 | 2839 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2005 | 379 | 0.050 |
Why?
|
| Child, Preschool | 7 | 2018 | 14805 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 1437 | 0.050 |
Why?
|
| Genetic Vectors | 2 | 2013 | 970 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2016 | 310 | 0.050 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2002 | 37 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 440 | 0.050 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2021 | 57 | 0.050 |
Why?
|
| Graft Survival | 3 | 2011 | 558 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2007 | 1206 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 247 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 198 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 2004 | 392 | 0.040 |
Why?
|
| CD5 Antigens | 2 | 2010 | 36 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 1334 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 345 | 0.040 |
Why?
|
| Liver | 1 | 1986 | 1877 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 29 | 0.040 |
Why?
|
| Philadelphia Chromosome | 1 | 1998 | 43 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 31 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2018 | 42 | 0.040 |
Why?
|
| Genes, Viral | 1 | 1998 | 186 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 252 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2018 | 70 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 195 | 0.040 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 1997 | 3 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 1998 | 59 | 0.040 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1998 | 102 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1139 | 0.030 |
Why?
|
| Mitosporic Fungi | 1 | 1997 | 8 | 0.030 |
Why?
|
| Erythropoiesis | 1 | 1997 | 43 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 99 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2018 | 3174 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2012 | 727 | 0.030 |
Why?
|
| BK Virus | 1 | 2017 | 61 | 0.030 |
Why?
|
| Skin Diseases | 1 | 1998 | 133 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1998 | 248 | 0.030 |
Why?
|
| Whole-Body Irradiation | 2 | 2006 | 61 | 0.030 |
Why?
|
| Mycoses | 1 | 1997 | 118 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2018 | 306 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2173 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 133 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2014 | 6576 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 241 | 0.030 |
Why?
|
| Phenotype | 2 | 2018 | 4553 | 0.030 |
Why?
|
| Kinetics | 2 | 1986 | 1355 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2016 | 310 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 866 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 389 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 569 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2013 | 70 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 73 | 0.030 |
Why?
|
| Hepatitis C | 1 | 1997 | 390 | 0.030 |
Why?
|
| Etoposide | 1 | 2013 | 120 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 691 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2013 | 296 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 1327 | 0.020 |
Why?
|
| Cell Separation | 1 | 2013 | 234 | 0.020 |
Why?
|
| South America | 1 | 2012 | 42 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3739 | 0.020 |
Why?
|
| Immunotherapy | 2 | 2011 | 746 | 0.020 |
Why?
|
| North America | 1 | 2012 | 260 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 836 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2012 | 132 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 417 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 110 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 362 | 0.020 |
Why?
|
| Infant | 3 | 2014 | 13173 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3399 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 526 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1735 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 68 | 0.020 |
Why?
|
| Risk Factors | 3 | 2013 | 11098 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2009 | 157 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2010 | 161 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 781 | 0.020 |
Why?
|
| Stem Cells | 1 | 2014 | 753 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2009 | 121 | 0.020 |
Why?
|
| Immunity | 1 | 2009 | 188 | 0.020 |
Why?
|
| Medical Records | 1 | 2009 | 193 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1615 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2010 | 197 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 1988 | 4 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 315 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1988 | 145 | 0.020 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2008 | 108 | 0.020 |
Why?
|
| Living Donors | 1 | 2008 | 118 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1494 | 0.020 |
Why?
|
| Half-Life | 1 | 1988 | 160 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 362 | 0.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2007 | 22 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 825 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 138 | 0.020 |
Why?
|
| Chemistry | 1 | 1986 | 61 | 0.020 |
Why?
|
| Electrochemistry | 1 | 1986 | 25 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1986 | 88 | 0.020 |
Why?
|
| Drug Stability | 1 | 1986 | 62 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2009 | 294 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2006 | 148 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2006 | 108 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2005 | 16 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 44 | 0.020 |
Why?
|
| Pneumonia | 1 | 2009 | 342 | 0.020 |
Why?
|
| Siblings | 1 | 2006 | 198 | 0.020 |
Why?
|
| CD52 Antigen | 1 | 2005 | 7 | 0.020 |
Why?
|
| Biopsy | 1 | 2009 | 1301 | 0.020 |
Why?
|
| United States | 1 | 2021 | 11684 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2005 | 83 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 215 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1986 | 364 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2005 | 93 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 716 | 0.010 |
Why?
|
| Virus Activation | 1 | 2005 | 85 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2005 | 246 | 0.010 |
Why?
|
| Texas | 1 | 2013 | 3693 | 0.010 |
Why?
|
| Immune System | 1 | 2005 | 98 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2005 | 151 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2005 | 333 | 0.010 |
Why?
|
| Methotrexate | 1 | 2006 | 355 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 34 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 444 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 52 | 0.010 |
Why?
|
| Age Factors | 1 | 2011 | 2988 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2008 | 1484 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2004 | 105 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 2004 | 54 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2005 | 440 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 2297 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2011 | 2025 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 1627 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 2211 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 152 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2005 | 381 | 0.010 |
Why?
|
| Viral Load | 1 | 2004 | 412 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 191 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 773 | 0.010 |
Why?
|
| Antibodies | 1 | 2004 | 382 | 0.010 |
Why?
|
| Horses | 1 | 2001 | 102 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2004 | 538 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 702 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2001 | 264 | 0.010 |
Why?
|
| Cell Movement | 1 | 2004 | 917 | 0.010 |
Why?
|
| Rabbits | 1 | 2001 | 730 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 756 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 7173 | 0.010 |
Why?
|
| Data Collection | 1 | 2001 | 396 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2001 | 341 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 1787 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 3753 | 0.010 |
Why?
|
| Erythroid Precursor Cells | 1 | 1997 | 24 | 0.010 |
Why?
|
| Aspergillus fumigatus | 1 | 1997 | 44 | 0.010 |
Why?
|
| Global Health | 1 | 2001 | 619 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2001 | 1334 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2006 | 3160 | 0.010 |
Why?
|
| HIV Infections | 1 | 2002 | 2068 | 0.000 |
Why?
|
| Animals | 1 | 2001 | 36407 | 0.000 |
Why?
|